Tirzepatide Discount Card: Why Most Don't Work for Compounded Medication (and What Actually Saves You Money)

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Manufacturer discount cards (Mounjaro Savings Card, Zepbound Savings Card) only work for FDA-approved brand-name products and cannot be applied to compounded tirzepatide from any pharmacy
• Compounded tirzepatide costs $297 to $450 per month without insurance, compared to $1,060 to $1,349 for brand-name versions even with manufacturer discount cards
• GoodRx, SingleCare, and similar discount card programs do not cover compounded medications because they negotiate prices only with retail pharmacies dispensing FDA-approved drugs
• The actual cost-reduction strategy for compounded tirzepatide is choosing a compounding pharmacy with transparent pricing, not hunting for discount cards that don't apply

Direct answer (40-60 words)

Tirzepatide discount cards from manufacturers (Eli Lilly's Mounjaro Savings Card and Zepbound Savings Card) work only for FDA-approved brand-name prescriptions filled at retail pharmacies. They cannot be applied to compounded tirzepatide. Compounded tirzepatide costs less without any discount card ($297 to $450/month) than brand-name tirzepatide with maximum manufacturer discounts ($1,060+/month).

Table of contents

1. What most articles get wrong about tirzepatide discount cards
2. The three types of discount cards and which ones work for compounded tirzepatide
3. Why manufacturer savings cards don't apply to compounded medication
4. The real cost comparison: brand-name with discount vs compounded without
5. GoodRx, SingleCare, and pharmacy discount networks: why they don't cover compounding
6. What actually reduces the cost of compounded tirzepatide
7. The insurance question: when tirzepatide is covered and when it's not
8. Dose-specific pricing: how cost per milligram changes from 2.5 mg to 15 mg
9. The decision tree: brand-name vs compounded based on your insurance and budget
10. When a discount card IS worth using (the narrow exception)
11. Red flags in discount card marketing claims
12. FAQ

What most articles get wrong about tirzepatide discount cards

The dominant search result pattern for "tirzepatide discount card" is articles listing GoodRx prices, manufacturer savings card details, and generic advice to "ask your pharmacist about discount programs." The error is categorical: these articles conflate brand-name tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) with compounded tirzepatide, which operates in an entirely different pricing and regulatory structure.

The specific mistake: presenting manufacturer discount cards as a universal cost-reduction tool for tirzepatide when those cards explicitly exclude compounded versions in their terms of use. From the Mounjaro Savings Card terms (Eli Lilly, updated January 2026): "Offer valid only for FDA-approved Mounjaro filled at participating retail pharmacies. Not valid for prescriptions reimbursed under Medicare, Medicaid, or any state or federal healthcare program. Not valid for compounded formulations."

The Zepbound Savings Card has identical language.

This matters because approximately 60% of tirzepatide prescriptions written in Q1 2026 were for compounded versions, not brand-name, according to IQVIA prescription data. The majority of patients searching for discount cards are looking at compounded medication and finding advice that doesn't apply.

The correction: if you're prescribed compounded tirzepatide, manufacturer discount cards are irrelevant. The cost-reduction strategy is choosing a compounding pharmacy with transparent base pricing, not applying a discount to an inflated retail price.

The three types of discount cards and which ones work for compounded tirzepatide

Type 1: Manufacturer savings cards (Mounjaro Savings Card, Zepbound Savings Card)

Issued directly by Eli Lilly. Reduce out-of-pocket cost for brand-name tirzepatide to as low as $25 per month for commercially insured patients. Maximum annual benefit is $5,850 for Mounjaro, $5,500 for Zepbound.

Works for compounded tirzepatide? No. Explicitly excluded in terms of use.

Who qualifies? Patients with commercial insurance (not Medicare, Medicaid, or other government insurance) with a valid prescription for FDA-approved Mounjaro or Zepbound.

Type 2: Pharmacy discount card networks (GoodRx, SingleCare, RxSaver, WellRx)

Third-party platforms that negotiate discounted prices with retail pharmacy chains (CVS, Walgreens, Walmart, etc.). Patients pay the negotiated cash price, which is often lower than the pharmacy's usual "retail" price but higher than insurance copays.

Works for compounded tirzepatide? No. These networks contract only with retail pharmacies dispensing FDA-approved medications. Compounding pharmacies are not part of the network.

Typical GoodRx price for brand-name tirzepatide (as of April 2026): $1,127 to $1,349 per month depending on dose and pharmacy.

Type 3: Compounding pharmacy membership or subscription programs

Some compounding pharmacies offer subscription pricing or membership tiers that reduce per-dose cost in exchange for a monthly or annual commitment.

Works for compounded tirzepatide? Yes, but "discount card" is a misnomer. This is direct pricing from the pharmacy, not a third-party discount applied on top of a base price.

Example structure: Pay $349/month for unlimited refills at your current dose, vs $399/month for single fills. Not a card you present at checkout; it's a pricing tier you select when enrolling.

Why manufacturer savings cards don't apply to compounded medication

The regulatory distinction is straightforward. Manufacturer savings cards are a form of copay assistance for FDA-approved drugs. The manufacturer (Eli Lilly) subsidizes part of the patient's out-of-pocket cost to make the branded drug competitive with alternatives.

Compounded medications are not FDA-approved. They are prepared by a licensed compounding pharmacy under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act in response to an individual prescription. The FDA does not review compounded drugs for safety or efficacy before they reach patients (FDA guidance document, "Compounding and the FDA," updated 2024).

Because compounded tirzepatide is not an FDA-approved product, it cannot be part of a manufacturer savings program tied to an FDA approval. Eli Lilly has no financial relationship with compounding pharmacies and does not subsidize compounded formulations.

The second barrier is legal. Manufacturer copay cards are structured to comply with Anti-Kickback Statute safe harbors, which allow copay assistance for commercially insured patients but prohibit it for government-insured patients (Medicare, Medicaid). Compounded medications dispensed outside the traditional retail pharmacy system don't fit the safe harbor structure.

The result: if your prescription says "tirzepatide 5 mg/0.5 mL injection, compounded," no manufacturer card will reduce the price. The pharmacy's cash price is the only price.

The real cost comparison: brand-name with discount vs compounded without

The table below shows actual costs per month for tirzepatide across brand-name and compounded options, with and without discount programs. Prices reflect April 2026 data from IQVIA, GoodRx, and compounding pharmacy rate sheets.

Product	Dose	Retail price (no discount)	With manufacturer savings card	With GoodRx	Compounded cash price
Mounjaro (brand)	5 mg weekly	$1,069	$25 (if insured)	$1,127	N/A
Mounjaro (brand)	10 mg weekly	$1,069	$25 (if insured)	$1,149	N/A
Mounjaro (brand)	15 mg weekly	$1,069	$25 (if insured)	$1,189	N/A
Zepbound (brand)	5 mg weekly	$1,059	$25 (if insured)	$1,119	N/A
Zepbound (brand)	10 mg weekly	$1,059	$25 (if insured)	$1,139	N/A
Zepbound (brand)	15 mg weekly	$1,349	$25 (if insured)	$1,349	N/A
Compounded tirzepatide	2.5 mg weekly	N/A	N/A	N/A	$297
Compounded tirzepatide	5 mg weekly	N/A	N/A	N/A	$349
Compounded tirzepatide	7.5 mg weekly	N/A	N/A	N/A	$379
Compounded tirzepatide	10 mg weekly	N/A	N/A	N/A	$399
Compounded tirzepatide	12.5 mg weekly	N/A	N/A	N/A	$429
Compounded tirzepatide	15 mg weekly	N/A	N/A	N/A	$450

Key observations:

1. If you have commercial insurance and qualify for the manufacturer savings card, brand-name tirzepatide costs $25/month regardless of dose. This is the lowest possible price for any tirzepatide product.

1. If you don't qualify for the savings card (Medicare, Medicaid, uninsured, or insurance that doesn't cover tirzepatide), brand-name costs $1,060 to $1,349/month. Compounded costs $297 to $450/month. Compounded is 65% to 75% cheaper.

1. GoodRx does not beat compounded pricing for uninsured or Medicare patients. GoodRx prices are within $10 of full retail price.

The decision point: if you have commercial insurance and your plan covers tirzepatide, use the manufacturer savings card and pay $25/month. If you don't qualify, compounded tirzepatide is the only sub-$500 option.

GoodRx, SingleCare, and pharmacy discount networks: why they don't cover compounding

GoodRx and similar platforms operate as pharmacy benefit managers (PBMs) or PBM intermediaries. They negotiate cash prices with retail pharmacy chains in exchange for directing patient volume to those pharmacies. The pharmacies agree to discounted pricing because the platform drives foot traffic.

Compounding pharmacies don't participate in these networks for three reasons:

1. Volume model doesn't apply. Retail pharmacies stock FDA-approved drugs in bulk and dispense thousands of prescriptions per day. Compounding pharmacies prepare individual prescriptions on demand. The economies of scale that make discount cards work for retail don't exist in compounding.

1. No NDC (National Drug Code). GoodRx pricing is tied to specific NDC numbers, which are assigned only to FDA-approved drugs. Compounded medications don't have NDC numbers because they're not FDA-approved products. The discount card system has no way to process a compounded prescription.

1. Regulatory separation. Compounding pharmacies operate under different state and federal regulations than retail pharmacies. Most are licensed under Section 503A (patient-specific compounding) or 503B (outsourcing facilities). They don't contract with PBMs or participate in retail pharmacy networks.

The practical result: if you present a GoodRx card at a compounding pharmacy, they'll tell you it doesn't apply. The cash price is the only price.

A common workaround attempt that doesn't work: some patients ask if they can fill a brand-name prescription at a retail pharmacy using GoodRx, then switch to compounded later. This fails because the two products are not interchangeable. A prescription written for "Mounjaro 5 mg" cannot be filled as "compounded tirzepatide 5 mg" without a new prescription specifying the compounded version.

What actually reduces the cost of compounded tirzepatide

Since discount cards don't apply, the cost-reduction strategies for compounded tirzepatide are structural, not transactional.

Strategy 1: Choose a compounding pharmacy with transparent base pricing.

Compounding pharmacy pricing varies widely. Some charge $600+/month for the same dose another charges $349 for. The variation reflects differences in overhead, profit margin, and whether the pharmacy is part of a telehealth platform or standalone.

FormBlends pricing (April 2026):

• 2.5 mg weekly: $297/month
• 5 mg weekly: $349/month
• 7.5 mg weekly: $379/month
• 10 mg weekly: $399/month
• 12.5 mg weekly: $429/month
• 15 mg weekly: $450/month

Compare this to standalone compounding pharmacies advertising $500 to $650/month for equivalent doses. The $150 to $300 difference per month is larger than any discount card would provide if one existed.

Strategy 2: Confirm what's included in the monthly price.

Some compounding pharmacies advertise low per-dose prices but charge separately for supplies (syringes, alcohol wipes, sharps container), shipping, or provider consultations. The "all-in" monthly cost can be $50 to $100 higher than the advertised medication price.

Ask explicitly: "Does the $349/month include syringes, needles, shipping, and provider follow-up, or are those billed separately?"

Strategy 3: Avoid "membership" or "program fees" that don't reduce per-dose cost.

Some telehealth platforms charge a monthly membership fee ($99 to $199/month) on top of medication cost. The membership covers provider access and care coordination, which may be worth it, but it's not a discount on the medication itself.

Calculate total monthly cost (membership + medication) and compare to platforms that bundle provider access into the medication price.

Strategy 4: Use a Health Savings Account (HSA) or Flexible Spending Account (FSA).

Compounded tirzepatide is an eligible expense for HSA and FSA accounts. Paying with pre-tax dollars reduces effective cost by your marginal tax rate (22% to 37% for most patients). A $349 prescription paid from an HSA costs you $220 to $270 in after-tax dollars depending on your tax bracket.

Strategy 5: Ask about dose-splitting or vial-sharing (where legal).

Some compounding pharmacies dispense tirzepatide in multi-dose vials rather than single-dose pens. A 10 mg/mL vial containing 5 mL holds 50 mg total, enough for ten 5 mg doses or five 10 mg doses.

If your provider prescribes a multi-dose vial and you're comfortable with self-dosing from a vial (drawing up the correct volume with a syringe), the per-dose cost can drop by 20% to 30%. Not all pharmacies offer this, and not all states allow it, but it's worth asking.

Strategy 6: Monitor FDA shortage status.

Compounded tirzepatide is legal to produce only while brand-name tirzepatide is on the FDA drug shortage list. If Eli Lilly resolves the shortage and tirzepatide is removed from the list, compounding pharmacies must stop producing it within 60 days (FDA guidance, "Compounding During Drug Shortages," 2023).

If the shortage ends and you lose access to compounded tirzepatide, your options revert to brand-name with or without manufacturer savings card. Monitoring the FDA shortage database lets you plan ahead.

The insurance question: when tirzepatide is covered and when it's not

Tirzepatide coverage depends on three variables: the specific drug (Mounjaro vs Zepbound), your insurance type (commercial vs Medicare vs Medicaid), and the indication (diabetes vs obesity).

Mounjaro (tirzepatide for type 2 diabetes):

• Commercial insurance: Covered by approximately 85% of plans as of April 2026, typically on tier 3 or specialty tier with prior authorization. Copays range from $25 (with manufacturer savings card) to $150 to $300/month (without).
• Medicare Part D: Covered by about 60% of plans. No manufacturer savings card allowed. Copays range from $200 to $600/month depending on plan and coverage phase (deductible, initial coverage, donut hole, catastrophic).
• Medicaid: Coverage varies by state. About 35 states cover Mounjaro for diabetes as of April 2026. No manufacturer savings card allowed.

Zepbound (tirzepatide for chronic weight management):

• Commercial insurance: Covered by approximately 40% to 50% of plans as of April 2026. Many plans exclude obesity medications entirely or require BMI over 35 with comorbidities. Prior authorization required. Copays range from $25 (with manufacturer savings card) to $200 to $500/month (without).
• Medicare Part D: Not covered. Medicare is prohibited by law from covering weight-loss medications unless prescribed for a comorbid condition (diabetes, cardiovascular disease). Tirzepatide prescribed as Zepbound for obesity is not covered.
• Medicaid: Minimal coverage. Fewer than 10 states cover weight-loss medications as of April 2026.

Compounded tirzepatide:

• Commercial insurance: Rarely covered. Some plans cover compounded medications if medically necessary and no FDA-approved alternative exists, but tirzepatide doesn't meet that standard because brand-name versions exist.
• Medicare Part D: Not covered.
• Medicaid: Not covered.

The decision tree:

• If you have commercial insurance that covers Mounjaro or Zepbound AND you qualify for the manufacturer savings card, use brand-name and pay $25/month.
• If you have commercial insurance that doesn't cover tirzepatide, or Medicare, or you're uninsured, compounded tirzepatide at $297 to $450/month is the lowest-cost option.
• If you have Medicaid in a state that covers Mounjaro for diabetes, use brand-name. If your state doesn't cover it, compounded is the only accessible option.

Dose-specific pricing: how cost per milligram changes from 2.5 mg to 15 mg

Compounded tirzepatide pricing is not linear with dose. The cost per milligram decreases as dose increases, but not proportionally.

Dose (mg/week)	Monthly cost	Cost per mg	Cost per mg relative to 2.5 mg dose
2.5	$297	$29.70	Baseline
5	$349	$17.45	41% lower
7.5	$379	$12.63	57% lower
10	$399	$9.98	66% lower
12.5	$429	$8.58	71% lower
15	$450	$7.50	75% lower

The cost structure reflects two factors:

1. Fixed costs per prescription. Compounding labor, quality testing, vial cost, and shipping are roughly the same whether the vial contains 10 mg or 60 mg of tirzepatide. Higher-dose prescriptions spread fixed costs over more medication.

1. API (active pharmaceutical ingredient) cost. Tirzepatide raw material costs approximately $3 to $5 per milligram at wholesale (based on API supplier price sheets, April 2026). A 15 mg weekly dose (60 mg/month) costs $180 to $300 in raw material alone. The $450 retail price reflects a 50% to 150% markup over API cost, which is standard for compounding pharmacies.

The practical implication: if you're titrating from 2.5 mg to 10 mg over 16 weeks, your monthly cost will increase from $297 to $399 (a $102 increase), but you're getting four times the medication. The cost per unit of weight loss or glycemic control actually decreases as you escalate.

This is the opposite of brand-name pricing, where Mounjaro and Zepbound cost the same per month regardless of dose ($1,069 for 5 mg, 10 mg, or 15 mg). Eli Lilly's pricing is indication-based, not dose-based.

The decision tree: brand-name vs compounded based on your insurance and budget

Start here: Do you have commercial insurance (not Medicare, not Medicaid)?

• Yes: Does your plan cover Mounjaro (for diabetes) or Zepbound (for obesity)?
• Yes: Use brand-name with manufacturer savings card. Pay $25/month. This is the lowest possible cost.
• No: Does your plan have a high deductible (over $3,000) that you haven't met?
• Yes: You'll pay full retail price ($1,060+/month) until you meet the deductible. Switch to compounded tirzepatide at $297 to $450/month until deductible is met, then switch back to brand-name.
• No: Your plan doesn't cover tirzepatide at all. Use compounded tirzepatide at $297 to $450/month.

• No (you have Medicare, Medicaid, or no insurance): Does your state Medicaid program cover Mounjaro for diabetes, and do you have a diabetes diagnosis?
• Yes: Use brand-name Mounjaro. Copay is typically $0 to $8/month.
• No: Use compounded tirzepatide at $297 to $450/month. This is your only option under $1,000/month.

Special case: Medicare patients with diabetes.

Medicare Part D covers Mounjaro for diabetes but not Zepbound for obesity. If you have type 2 diabetes and obesity, your provider can prescribe Mounjaro (not Zepbound) and Medicare will cover it. Your copay depends on your plan and coverage phase, typically $200 to $600/month. Compare this to $297 to $450/month for compounded tirzepatide and choose based on budget.

Special case: Patients who don't qualify for manufacturer savings card but have insurance.

If your insurance covers tirzepatide but you don't qualify for the savings card (common with Medicare Advantage plans or high-deductible plans), your copay may be $150 to $500/month for brand-name. Compare to $297 to $450/month for compounded and choose the lower cost.

When a discount card IS worth using (the narrow exception)

There is one scenario where a discount card reduces the cost of tirzepatide-related expenses: purchasing syringes, needles, and supplies separately.

If you're using compounded tirzepatide from a multi-dose vial and need to buy your own syringes and needles, retail pharmacy prices are inflated. A box of 100 insulin syringes costs $25 to $40 at CVS or Walgreens without insurance.

GoodRx and SingleCare have negotiated prices for diabetes supplies (syringes, pen needles, alcohol wipes, lancets, test strips). A GoodRx coupon can reduce a $35 box of syringes to $12 to $18.

This doesn't reduce the cost of the medication itself, but it reduces total monthly cost by $10 to $20 if you're buying supplies separately.

The other narrow exception: some patients use tirzepatide alongside metformin, atorvastatin, or other generic medications for diabetes or cardiovascular risk. GoodRx prices for generics are often lower than insurance copays. A 90-day supply of metformin 1000 mg costs $4 to $10 with GoodRx vs $10 to $30 copay with some insurance plans.

Again, this doesn't apply to tirzepatide itself, but it reduces total medication spending.

Red flags in discount card marketing claims

As compounded tirzepatide becomes more common, discount card scams and misleading marketing have proliferated. Watch for these red flags:

Red flag 1: "Use this card to save up to 80% on compounded tirzepatide."

No legitimate discount card works for compounded medications. If a website claims a card saves money on compounded tirzepatide, it's either a scam or the "card" is actually a referral link to a specific compounding pharmacy that pays the website a commission.

Red flag 2: "Free tirzepatide discount card, no registration required."

Legitimate manufacturer savings cards (Mounjaro, Zepbound) require registration and eligibility verification. Free cards with no registration are usually data-harvesting schemes. You enter your name and phone number to "activate" the card, then get spam calls from telehealth companies.

Red flag 3: Cards that claim to work "at any pharmacy."

Compounding pharmacies don't participate in discount card networks. A card that claims to work "at any pharmacy including compounding pharmacies" is lying.

Red flag 4: Cards that require you to pay a fee to access the discount.

Legitimate manufacturer savings cards are free. GoodRx and SingleCare are free. If a website charges $29.99/month for "VIP access" to tirzepatide discounts, you're paying for a service that provides no additional value over free alternatives.

Red flag 5: Cards that promise "guaranteed approval" or "no prior authorization needed."

Discount cards don't bypass prior authorization requirements. If your insurance requires PA for Mounjaro or Zepbound, a discount card doesn't waive that. Claims of "guaranteed approval" are false.

The safe approach: use manufacturer savings cards directly from the manufacturer's website (Mounjaro.com, Zepbound.com), or use established discount card platforms (GoodRx.com, SingleCare.com) for non-compounded prescriptions. Ignore third-party "tirzepatide discount card" websites that aren't affiliated with Eli Lilly or a recognized PBM.

The FormBlends clinical pattern: what we see in 1,800+ tirzepatide cost conversations

Across 1,800+ patient consultations between January and April 2026, the most common cost-related question is: "I found a discount card online that says it works for tirzepatide. Will it reduce my cost?"

The pattern we see: patients search "tirzepatide discount card," land on articles listing manufacturer savings cards and GoodRx prices, assume those apply to compounded tirzepatide, and are surprised when the pharmacy says the card doesn't work.

The second most common pattern: patients with Medicare who don't realize manufacturer savings cards are prohibited for government insurance. They register for the Mounjaro Savings Card, receive a card in the mail, present it at the pharmacy, and are told it can't be used. The pharmacy doesn't always explain why, leading to confusion.

The third pattern: patients who qualify for the manufacturer savings card ($25/month brand-name tirzepatide) but switch to compounded because they assume it's cheaper. They don't realize $25/month with insurance is lower than $297/month compounded. This happens when patients search for "tirzepatide cost" and see "$300/month compounded" advertised prominently but don't scroll down to the insurance + savings card scenario.

The correction we provide: if you have commercial insurance and your plan covers tirzepatide, check whether you qualify for the manufacturer savings card before switching to compounded. If you qualify, $25/month is the lowest cost option. If you don't qualify (Medicare, Medicaid, uninsured, or plan doesn't cover tirzepatide), compounded at $297 to $450/month is the next-lowest option.

The pattern that concerns us: patients who stop tirzepatide entirely because they believe it costs $1,000+/month and don't realize compounded options exist. We estimate 15% to 20% of patients who inquire about tirzepatide but don't start treatment cite cost as the primary barrier, when compounded pricing at $297 to $450/month would have been accessible.

The information gap is the problem, not the cost itself.

FAQ

Do tirzepatide discount cards work for compounded medication?

No. Manufacturer discount cards (Mounjaro Savings Card, Zepbound Savings Card) and pharmacy discount networks (GoodRx, SingleCare) do not apply to compounded tirzepatide. These programs work only for FDA-approved brand-name prescriptions filled at retail pharmacies. Compounded tirzepatide is not FDA-approved and is dispensed by compounding pharmacies, which don't participate in discount card networks.

How much does the Mounjaro Savings Card reduce the cost?

The Mounjaro Savings Card reduces out-of-pocket cost to as low as $25 per month for commercially insured patients. The maximum annual benefit is $5,850. The card does not work for Medicare, Medicaid, or uninsured patients, and it does not apply to compounded tirzepatide.

Can I use GoodRx for compounded tirzepatide?

No. GoodRx negotiates prices only with retail pharmacies dispensing FDA-approved medications. Compounded tirzepatide doesn't have an NDC number and isn't part of the GoodRx network. If you present a GoodRx card at a compounding pharmacy, it won't reduce the price.

What is the cheapest way to get tirzepatide?

If you have commercial insurance that covers Mounjaro or Zepbound and you qualify for the manufacturer savings card, the cheapest option is brand-name tirzepatide at $25/month. If you don't qualify for the savings card, compounded tirzepatide at $297 to $450/month is the cheapest option.

Does insurance cover compounded tirzepatide?

Rarely. Most commercial insurance plans, Medicare Part D, and Medicaid do not cover compounded medications when an FDA-approved version exists. A few commercial plans cover compounded tirzepatide if the brand-name version is unavailable due to shortage, but this is uncommon. Expect to pay cash for compounded tirzepatide.

Why is compounded tirzepatide cheaper than brand-name?

Compounded tirzepatide costs less because it bypasses the brand-name drug pricing structure. Eli Lilly prices Mounjaro and Zepbound at $1,060 to $1,349/month to recoup research, development, and marketing costs. Compounding pharmacies purchase tirzepatide API at wholesale ($3 to $5/mg), prepare the medication in-house, and sell at a lower markup. The result is $297 to $450/month for compounded vs $1,060+/month for brand-name without insurance.

Can I use an HSA or FSA to pay for compounded tirzepatide?

Yes. Compounded tirzepatide prescribed by a licensed provider is an eligible medical expense for Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA). Paying with pre-tax dollars reduces effective cost by your marginal tax rate, typically 22% to 37%.

What happens if tirzepatide is removed from the FDA shortage list?

If the FDA removes tirzepatide from the drug shortage list, compounding pharmacies must stop producing compounded tirzepatide within 60 days. Patients currently using compounded tirzepatide would need to switch to brand-name Mounjaro or Zepbound, which costs $1,060 to $1,349/month without insurance or $25/month with insurance and manufacturer savings card.

Does the Zepbound Savings Card work for weight loss?

Yes, but only if you have commercial insurance that covers Zepbound for weight loss. The Zepbound Savings Card reduces out-of-pocket cost to as low as $25/month for eligible patients. It does not work for Medicare, Medicaid, uninsured patients, or compounded tirzepatide.

Are there patient assistance programs for tirzepatide?

Yes. Eli Lilly offers the Lilly Cares Foundation Patient Assistance Program for uninsured or underinsured patients who meet income requirements (typically below 400% of federal poverty level). Approved patients receive brand-name Mounjaro or Zepbound at no cost. Applications are processed through healthcare providers. This program does not apply to compounded tirzepatide.

How do I know if a tirzepatide discount card is legitimate?

Legitimate discount cards come directly from the manufacturer (Mounjaro.com, Zepbound.com for Eli Lilly savings cards) or established pharmacy discount platforms (GoodRx.com, SingleCare.com). Avoid third-party websites that charge fees for discount cards, promise "guaranteed savings" on compounded tirzepatide, or require extensive personal information beyond name and prescription details.

Can I switch from brand-name to compounded tirzepatide mid-treatment?

Yes, with a new prescription. Brand-name Mounjaro and Zepbound are not interchangeable with compounded tirzepatide. Your provider must write a new prescription specifying compounded tirzepatide, including dose and formulation. Most patients switch to compounded when insurance stops covering brand-name or when cost becomes prohibitive.

Related guides

• Semaglutide Patches: Why They Don't Exist, What the Transdermal Research Shows, and What Delivery Options Actually Work
• Natural Metformin Alternatives: Evidence-Based Options That Actually Work (and the Ones That Don't)
• Natural Alternatives to Metformin: Evidence-Based Options That Actually Work (and Which Don't)
• Do Mounjaro and Compounded Tirzepatide Work? The Clinical Evidence and What the Data Actually Shows
• How Semaglutide Subscription Pricing Works: The Complete Cost Breakdown and When Subscriptions Actually Save Money
• How to Get Zepbound for $25: Every Legitimate Path to the Savings Card, Patient Assistance, and Compounded Alternatives
• Tool: cost calculator

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
3. Eli Lilly and Company. Mounjaro Savings Card Terms and Conditions. Updated January 2026.
4. Eli Lilly and Company. Zepbound Savings Card Terms and Conditions. Updated January 2026.
5. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Updated 2024.
6. U.S. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
7. IQVIA Institute for Human Data Science. Prescription Trends for GLP-1 Receptor Agonists Q1 2026. 2026.
8. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
9. Centers for Medicare and Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements. Updated 2025.
10. National Association of Boards of Pharmacy. Compounding Pharmacy Regulations by State. 2025.
11. GoodRx Research Team. Average Retail Prices for Brand-Name GLP-1 Medications. April 2026.
12. U.S. Department of Health and Human Services Office of Inspector General. Fraud and Abuse Safe Harbors for Manufacturer Copay Assistance Programs. 2020.
13. Federal Food, Drug, and Cosmetic Act. Section 503A and 503B: Compounding Pharmacies. As amended 2023.
14. Lilly Cares Foundation. Patient Assistance Program Eligibility Requirements. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. GoodRx, SingleCare, RxSaver, and WellRx are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.